ES2179881T3 - Antagonistas de endotelina. - Google Patents
Antagonistas de endotelina.Info
- Publication number
- ES2179881T3 ES2179881T3 ES95928323T ES95928323T ES2179881T3 ES 2179881 T3 ES2179881 T3 ES 2179881T3 ES 95928323 T ES95928323 T ES 95928323T ES 95928323 T ES95928323 T ES 95928323T ES 2179881 T3 ES2179881 T3 ES 2179881T3
- Authority
- ES
- Spain
- Prior art keywords
- endotheline antagonists
- antagonists
- processes
- endotheline
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 102000002045 Endothelin Human genes 0.000 abstract 1
- 108050009340 Endothelin Proteins 0.000 abstract 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
SE DESCRIBE UN COMPUESTO DE FORMULA (I), O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, ASI COMO PROCEDIMIENTOS E INTERMEDIARIOS PARA LA PREPARACION DEL MISMO, Y UN METODO DE ANTAGONIZACION DE ENDOTELINA.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29334994A | 1994-08-19 | 1994-08-19 | |
US33471794A | 1994-11-04 | 1994-11-04 | |
US08/442,575 US5767144A (en) | 1994-08-19 | 1995-05-30 | Endothelin antagonists |
US49799895A | 1995-08-02 | 1995-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2179881T3 true ES2179881T3 (es) | 2003-02-01 |
Family
ID=27501591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95928323T Expired - Lifetime ES2179881T3 (es) | 1994-08-19 | 1995-08-04 | Antagonistas de endotelina. |
Country Status (13)
Country | Link |
---|---|
EP (2) | EP1186603A3 (es) |
JP (1) | JP3741441B2 (es) |
KR (2) | KR100447000B1 (es) |
AT (1) | ATE219077T1 (es) |
AU (1) | AU711832B2 (es) |
CA (2) | CA2517691A1 (es) |
DE (1) | DE69527072T2 (es) |
DK (1) | DK0776324T3 (es) |
ES (1) | ES2179881T3 (es) |
HK (1) | HK1008328A1 (es) |
IL (2) | IL114894A (es) |
PT (1) | PT776324E (es) |
WO (1) | WO1996006095A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5852046A (en) * | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
US5767144A (en) * | 1994-08-19 | 1998-06-16 | Abbott Laboratories | Endothelin antagonists |
US7208517B1 (en) | 1994-08-19 | 2007-04-24 | Abbott Labortories | Endothelin antagonists |
US6162927A (en) | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
AU2262097A (en) * | 1996-02-13 | 1997-09-02 | Abbott Laboratories | Novel benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivat ives as endothelin antagonists |
AU2763602A (en) * | 1996-02-13 | 2002-05-16 | Abbott Laboratories | Endothelin antagonists |
AU781355B2 (en) * | 1996-02-13 | 2005-05-19 | Abbott Laboratories | Novel benzo-1,3-dioxolyl-and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists |
BR9707394A (pt) * | 1996-02-13 | 1999-04-06 | Abbott Lab | Derivados de ácido 4-(benzo-1,3-dioxolil) pirrolidino-3-carboxílico como antagonistas endotelina |
US5801250A (en) * | 1996-12-13 | 1998-09-01 | Abbott Laboratories | Process for the stereoselective production of nitro-enamine compounds |
US6030975A (en) * | 1997-03-14 | 2000-02-29 | Basf Aktiengesellschaft | Carboxylic acid derivatives, their preparation and use in treating cancer |
HUP0002681A3 (en) * | 1997-06-17 | 2001-09-28 | Abbott Lab | Pyrrolidine carboxylic acid derivatives as endothelin antagonists and pharmaceutical compositions containing the same |
TR200101234T2 (tr) * | 1997-08-04 | 2002-06-21 | Abbott Laboratories | Endotelin antagonistleri. |
IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
US6339087B1 (en) | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
DE19743681A1 (de) * | 1997-10-02 | 1999-04-08 | Knoll Ag | Methode zur Verhinderung der Transplantatabstoßung |
US6410554B1 (en) | 1998-03-23 | 2002-06-25 | Merck & Co., Inc. | Combination therapy for the treatment of benign prostatic hyperplasia |
WO2000015611A1 (en) * | 1998-09-14 | 2000-03-23 | Warner-Lambert Company | Branched alkyl pyrrolidine-3-carboxylic acids |
CA2351631A1 (en) | 1998-11-20 | 2000-06-02 | F. Hoffmann-La Roche Ag | Piperidine quaternary salts-ccr-3 receptor antagonists |
WO2002017912A1 (en) * | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Endothelin antagonists |
US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
KR20070006774A (ko) | 2004-03-17 | 2007-01-11 | 노파르티스 아게 | 치료에서 레닌 억제제의 용도 |
CA2904447C (en) | 2007-08-22 | 2017-01-03 | Abbvie Deutschland Gmbh & Co Kg | Therapy for complications of diabetes |
WO2011114103A1 (en) | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
US9376425B2 (en) | 2011-09-27 | 2016-06-28 | Amgen, Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
JP6266659B2 (ja) | 2013-02-28 | 2018-01-24 | アムジエン・インコーポレーテツド | 癌の治療のための安息香酸誘導体mdm2阻害剤 |
US9758495B2 (en) | 2013-03-14 | 2017-09-12 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
US8962675B1 (en) * | 2013-09-12 | 2015-02-24 | Abbvie Inc. | Atrasentan mandelate salts |
KR102091932B1 (ko) | 2018-08-16 | 2020-03-20 | 장남순 | 안전하고 간편한 접첩구조를 갖는 접이식 트램펄린 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3342833A (en) * | 1964-08-07 | 1967-09-19 | Shell Oil Co | Pyrrolidine production from aziridines and olefins |
RU2125980C1 (ru) * | 1991-11-05 | 1999-02-10 | Смитклайн Бичам Корпорейшн | Антагонисты эндотелиновых рецепторов, фармкомпозиция, способ их получения, способ подавления эндотелиновых рецепторов |
WO1994002474A1 (en) * | 1992-07-17 | 1994-02-03 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
-
1995
- 1995-08-04 CA CA002517691A patent/CA2517691A1/en not_active Abandoned
- 1995-08-04 DE DE69527072T patent/DE69527072T2/de not_active Expired - Lifetime
- 1995-08-04 KR KR1019970701079A patent/KR100447000B1/ko not_active IP Right Cessation
- 1995-08-04 WO PCT/US1995/009924 patent/WO1996006095A1/en active Search and Examination
- 1995-08-04 KR KR10-2004-7004682A patent/KR100483222B1/ko not_active IP Right Cessation
- 1995-08-04 EP EP01125462A patent/EP1186603A3/en not_active Withdrawn
- 1995-08-04 AU AU32137/95A patent/AU711832B2/en not_active Expired
- 1995-08-04 JP JP50810196A patent/JP3741441B2/ja not_active Expired - Lifetime
- 1995-08-04 DK DK95928323T patent/DK0776324T3/da active
- 1995-08-04 CA CA002195677A patent/CA2195677C/en not_active Expired - Lifetime
- 1995-08-04 AT AT95928323T patent/ATE219077T1/de active
- 1995-08-04 PT PT95928323T patent/PT776324E/pt unknown
- 1995-08-04 EP EP95928323A patent/EP0776324B1/en not_active Expired - Lifetime
- 1995-08-04 ES ES95928323T patent/ES2179881T3/es not_active Expired - Lifetime
- 1995-08-10 IL IL11489495A patent/IL114894A/xx not_active IP Right Cessation
- 1995-08-10 IL IL134905A patent/IL134905A/en not_active IP Right Cessation
-
1998
- 1998-07-15 HK HK98109192A patent/HK1008328A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL134905A0 (en) | 2001-05-20 |
HK1008328A1 (en) | 1999-05-07 |
EP1186603A3 (en) | 2003-07-09 |
AU3213795A (en) | 1996-03-14 |
CA2195677C (en) | 2005-11-08 |
EP0776324A1 (en) | 1997-06-04 |
DE69527072T2 (de) | 2003-02-13 |
CA2195677A1 (en) | 1996-02-29 |
JP3741441B2 (ja) | 2006-02-01 |
AU711832B2 (en) | 1999-10-21 |
DK0776324T3 (da) | 2002-10-07 |
IL134905A (en) | 2009-06-15 |
KR100483222B1 (ko) | 2005-04-15 |
IL114894A0 (en) | 1995-12-08 |
DE69527072D1 (de) | 2002-07-18 |
WO1996006095A1 (en) | 1996-02-29 |
CA2517691A1 (en) | 1996-02-29 |
JPH10504565A (ja) | 1998-05-06 |
KR20040045036A (ko) | 2004-05-31 |
EP1186603A2 (en) | 2002-03-13 |
KR100447000B1 (ko) | 2004-12-10 |
ATE219077T1 (de) | 2002-06-15 |
IL114894A (en) | 2003-04-10 |
KR970705561A (ko) | 1997-10-09 |
EP0776324B1 (en) | 2002-06-12 |
PT776324E (pt) | 2002-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2179881T3 (es) | Antagonistas de endotelina. | |
FI930970A (fi) | Imidazolderivat med bifenylsulfonylurea- eller bifenylsulfonyluretansidokedja, foerfaranden foer framstaellning av dessa och anvaendning av dessa | |
TR200200579T2 (tr) | Amino-tirazolpiridin türevleri. | |
DK0641325T3 (da) | Inhibitorer af retroviral protease | |
ATE305781T1 (de) | Non-peptidische vasopressin via antagonisten | |
ES2106825T3 (es) | Derivados de piperidina. | |
DE69511424D1 (de) | Antifungale sordaridinderivate | |
BR9815296A (pt) | Derivados de ácido carboxìlico 3-pirrolidina e ouso dos mesmos como antagonistas endotelina | |
SE9100920D0 (sv) | New active compounds | |
ES556864A0 (es) | Procedimiento para la obtencion de benzopiranos sustituidos. | |
DK0428313T3 (da) | Pyrimidonderivater samt analoge til behandling af astma og visse hudlidelser | |
ES2104509A1 (es) | Nuevos compuestos derivados de 2-(3,4-disustituido-1-piperazinil)-5-fluoropirimidina. | |
FI952420A0 (fi) | Glukopyranosidibentsotiofeenit | |
PT896822E (pt) | 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y | |
ATE165083T1 (de) | N-arylalkylphenylacetamidderivate | |
BR9810031A (pt) | Derivados de ácido pirrolidina carboxìlico como antagonistas á endotelina | |
MX9204939A (es) | Inhibidores 5-bis-aminometilen-1,3-dioxan-4,6-diona n,n',n'-trisubstituidas, de la acil coenzima a: colesterol-aciltransferasa. | |
BR9713998A (pt) | Uso de 17beta-dihidroequilenina como um antioxidante | |
ATE178071T1 (de) | Endothelin-antagonisierendes peptid | |
KR960015946U (ko) | 레이져 트리머의 양면 부품용 척 | |
MX9701220A (es) | Antagonistas de endotelina. |